General Information |
Board Constituency: |
None |
Is your organization legally registered in your country: |
Yes |
If yes, please enter your registration number: |
304617386 |
Organization Type - Primary: |
Private Sector |
Organization Type - Secondary: |
Company |
Organization Description: |
At Oxipit we create AI tools for global medical imaging. Our mission is to harness the latest AI and Machine Learning developments for better patient outcomes around the world. By utilizing Artificial Intelligence, we aim to address the global radiologist shortage and improve diagnostic quality. |
|
Do you know about the UNHLM declaration: |
Yes |
Other Organization Information |
Total number of staff in your organization: |
11 - 25 |
Number of full-time staff who are directly involved with TB: |
0 |
Number of part-time staff who are directly involved with TB: |
0 |
Number of volunteers who are directly involved with TB: |
0 |
|
How did you hear about the Stop TB Partnership: |
Media |
If you were informed or referred by another partner of the Stop TB Partnership please tell us who: |
|
Why do you wish join the Stop TB Partnership: |
Network with other partners |
|
Are you a member of a Stop TB national partnership: |
No |
Are you in contact with your national TB programme: |
No |
Please tell us how your organization is contributing to your country's national TB control plan: |
N/A. Oxipit provide AI powered chest xray reading to eliminate and auto-report any chest xrays that have no signs of disease. This feature (called 'ChestLink') is unique, class IIb certified, and massively reduces the workload on radiologists. The remaining studies are supported via Computer-Assisted Diagnosis (CAD) tool which are found in many other AI solutions. Finally, the Oxipit solution scans all chest x-ray studies to analyse for any reporting errors as well as provide statistical analysis. |
|
Geographical Reach |
Which country is your headquarters located in: |
Lithuania |
Which countries do you do operate in: (This includes countries you are conducting activities in) |
Australia Brazil Denmark Germany Greece Italy Lithuania Netherlands Poland Portugal Spain Sweden Switzerland Ukraine United Kingdom of Great Britain and Northern Ireland |